|
Age (years)
|
60 ± 11
|
58 ± 13
|
0.512
|
|
Men
|
13 (87%)
|
26 (89%)
|
0.767
|
|
New York Heart Association class
|
|
I – II
|
11
|
24
|
0.207
|
|
III – IV
|
5
|
5
| |
|
Diabetes mellitus
|
4 (27%)
|
3 (10%)
|
0.206
|
|
Atrial fibrillation
|
6 (40%)
|
4 (14%)
|
0.067
|
|
Nonsustained ventricular tachycardia
|
6 (40%)
|
11 (38%)
|
0.894
|
|
Serum creatinine (mg/dl)
|
0.87 ± 0.16
|
0.81 ± 0.25
|
0.406
|
|
Estimated glomerular filtration rate (ml min-1 1.73 m-2)
|
80.3 ± 12.2
|
79.8 ± 12.1
|
0.738
|
|
Complete left bundle brunch brock
|
2 (13%)
|
6 (21%)
|
0.549
|
|
QRS duration (ms)
|
101 ± 14
|
111 ± 32
|
0.173
|
|
Follow-up periods (years)
|
5.9 ± 3.2
|
4.4 ± 2.8
|
0.220
|
|
Pharmacological treatments
|
|
β blockers
|
15 (100%)
|
29 (100%)
|
>0.99
|
|
Carvedilol
|
13 (87%)
|
24 (83%)
|
0.737
|
|
Dose (mg/day)
|
11.3 ± 4.8
|
10.8 ± 5.3
|
0.761
|
|
Metoprolol
|
2 (13%)
|
5 (17%)
|
0.735
|
|
Dose (mg/day)
|
60.0 ± 28.2
|
56.0 ± 21.9
|
0.879
|
|
Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers
|
12 / 3 (100%)
|
24/5 (100%)
|
>0.99
|
|
Enalapril
|
10 (67%)
|
20 (69%)
|
0.877
|
|
Dose (mg/day)
|
5.2 ± 1.8
|
4.6 ± 0.9
|
0.318
|
|
Losartan
|
2 (13%)
|
3 (20%)
|
0.767
|
|
Dose (mg/day)
|
37.5 ± 17.7
|
41.7 ± 14.4
|
0.738
|
|
Loop diuretics
|
13 (87%)
|
27 (93%)
|
0.596
|
|
Spironolactone
|
7 (45%)
|
15 (52%)
|
0.751
|
|
Digitalis
|
11 (73%)’
|
20 (67%)
|
0.763
|
|
Amiodarone
|
1 (7%)
|
4 (14%)
|
0.647
|
